November 4, 2024 11:20 AM EST
News Briefing

No­vo, As­cendis to work on month­ly GLP-1; KalVista makes a roy­al­ty deal

ENDPOINTS

Plus, news about Disc Med­i­cine, OSE Im­munother­a­peu­tics, Cross­Bridge Bio, Lomond Ther­a­peu­tics, Re­lief Ther­a­peu­tics and Renexxion:

No­vo Nordisk, As­cendis Phar­ma ink deal: The Dan­ish drug­mak­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times